TY - JOUR
T1 - MDSC
T2 - Markers, development, states, and unaddressed complexity
AU - Hegde, Samarth
AU - Leader, Andrew M.
AU - Merad, Miriam
N1 - Funding Information:
We thank the Merad lab for providing feedback on this manuscript. S.H. was supported by National Cancer Institute predoctoral-to-postdoctoral fellowship K00 CA223043 . M.M. is funded by R01 CA190400 , U19 AI128949 , and R01 CA154947 .
Publisher Copyright:
© 2021
PY - 2021/5/11
Y1 - 2021/5/11
N2 - Myeloid-derived suppressor cells (MDSCs) are one of the most discussed biological entities in immunology. While the context and classification of this group of cells has evolved, MDSCs most commonly describe cells arising during chronic inflammation, especially late-stage cancers, and are defined by their T cell immunosuppressive functions. This MDSC concept has helped explain myeloid phenomena associated with disease outcome, but currently lacks clear definitions and a unifying framework across pathologies. Here, we propose such a framework to classify MDSCs as discrete cell states based on activation signals in myeloid populations leading to suppressive modes characterized by specific, measurable effects. Developing this level of knowledge of myeloid states across pathological conditions may ultimately transform how disparate diseases are grouped and treated.
AB - Myeloid-derived suppressor cells (MDSCs) are one of the most discussed biological entities in immunology. While the context and classification of this group of cells has evolved, MDSCs most commonly describe cells arising during chronic inflammation, especially late-stage cancers, and are defined by their T cell immunosuppressive functions. This MDSC concept has helped explain myeloid phenomena associated with disease outcome, but currently lacks clear definitions and a unifying framework across pathologies. Here, we propose such a framework to classify MDSCs as discrete cell states based on activation signals in myeloid populations leading to suppressive modes characterized by specific, measurable effects. Developing this level of knowledge of myeloid states across pathological conditions may ultimately transform how disparate diseases are grouped and treated.
UR - http://www.scopus.com/inward/record.url?scp=85105296055&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2021.04.004
DO - 10.1016/j.immuni.2021.04.004
M3 - Review article
C2 - 33979585
AN - SCOPUS:85105296055
SN - 1074-7613
VL - 54
SP - 875
EP - 884
JO - Immunity
JF - Immunity
IS - 5
ER -